JP2011505875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505875A5 JP2011505875A5 JP2010539824A JP2010539824A JP2011505875A5 JP 2011505875 A5 JP2011505875 A5 JP 2011505875A5 JP 2010539824 A JP2010539824 A JP 2010539824A JP 2010539824 A JP2010539824 A JP 2010539824A JP 2011505875 A5 JP2011505875 A5 JP 2011505875A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- acid sequence
- amino acid
- seq
- region comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 201000005787 hematologic cancer Diseases 0.000 claims description 15
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 108010005832 Leukosialin Proteins 0.000 claims 2
- 102000005931 Leukosialin Human genes 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1471607P | 2007-12-18 | 2007-12-18 | |
| US61/014,716 | 2007-12-18 | ||
| PCT/US2008/087515 WO2009079649A1 (en) | 2007-12-18 | 2008-12-18 | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183896A Division JP2013247963A (ja) | 2007-12-18 | 2013-09-05 | 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505875A JP2011505875A (ja) | 2011-03-03 |
| JP2011505875A5 true JP2011505875A5 (https=) | 2012-01-26 |
| JP5568478B2 JP5568478B2 (ja) | 2014-08-06 |
Family
ID=40578003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539824A Expired - Fee Related JP5568478B2 (ja) | 2007-12-18 | 2008-12-18 | 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法 |
| JP2013183896A Withdrawn JP2013247963A (ja) | 2007-12-18 | 2013-09-05 | 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183896A Withdrawn JP2013247963A (ja) | 2007-12-18 | 2013-09-05 | 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7982017B2 (https=) |
| EP (1) | EP2245063B1 (https=) |
| JP (2) | JP5568478B2 (https=) |
| KR (1) | KR101672271B1 (https=) |
| CN (2) | CN101918448A (https=) |
| AU (1) | AU2008338313B2 (https=) |
| BR (1) | BRPI0820452A2 (https=) |
| CA (1) | CA2706502C (https=) |
| DK (1) | DK2245063T3 (https=) |
| ES (1) | ES2550757T3 (https=) |
| HU (1) | HUE026846T2 (https=) |
| IL (1) | IL205487A (https=) |
| NZ (1) | NZ585959A (https=) |
| RU (1) | RU2528738C2 (https=) |
| SG (1) | SG186669A1 (https=) |
| TW (1) | TWI439545B (https=) |
| WO (1) | WO2009079649A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CA2652703C (en) | 2006-06-07 | 2018-08-28 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| JP5607530B2 (ja) | 2007-09-04 | 2014-10-15 | コンピュゲン エルティーディー． | ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| HUE026846T2 (en) | 2007-12-18 | 2016-08-29 | Bioalliance Cv | Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| KR101244708B1 (ko) | 2010-10-07 | 2013-03-18 | 기아자동차주식회사 | 측면 조립형 트랜스미션 마운트 |
| US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| CA2848985A1 (en) | 2012-02-01 | 2013-08-08 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US9089614B2 (en) | 2012-12-21 | 2015-07-28 | Bioalliance C.V. | Hydrophilic self-immolative linkers and conjugates thereof |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| EP2871190A1 (en) * | 2013-11-11 | 2015-05-13 | ATLAB Pharma | Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity |
| US9950077B2 (en) | 2014-06-20 | 2018-04-24 | Bioalliance C.V. | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| WO2016209079A1 (en) * | 2015-06-24 | 2016-12-29 | Aimm Therapeutics B.V. | Aml antigens and uses thereof |
| CA3001676C (en) | 2015-10-12 | 2022-12-06 | Aprogen Kic Inc. | Anti-cd43 antibody and use thereof for cancer treatment |
| US20180363000A1 (en) * | 2015-12-14 | 2018-12-20 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
| AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| IL260289B (en) | 2016-01-08 | 2022-08-01 | Bioalliance Cv | Tetravalent anti-psgl-1 antibodies and uses thereof |
| EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| US12054558B2 (en) * | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7578289B2 (ja) * | 2018-12-21 | 2024-11-06 | マルチチュード インコーポレーテッド | Ｍｕｃ１８に特異的な抗体 |
| WO2020132190A1 (en) | 2018-12-21 | 2020-06-25 | Multitude Inc. | Antibodies specific to muc18 |
| WO2021081515A2 (en) * | 2019-10-25 | 2021-04-29 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| US12290565B2 (en) | 2021-11-17 | 2025-05-06 | Altrubio Inc. | Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6808901B1 (en) | 1984-09-03 | 2004-10-26 | Celltech R&D Limited | Production of chimeric antibodies |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| DK0528767T3 (da) | 1991-08-21 | 2000-04-17 | Novartis Ag | antistofderivater |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| DK0814154T3 (da) | 1993-09-15 | 2009-08-31 | Novartis Vaccines & Diagnostic | Rekombinante alfavirusvektorer |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| AU686277B2 (en) | 1993-11-16 | 1998-02-05 | Pacira Pharmaceuticals, Inc. | Vesicles with controlled release of actives |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
| JP3613484B2 (ja) | 1994-10-18 | 2005-01-26 | 住友ダウ株式会社 | 耐電離放射線性カーボネート樹脂組成物及びそれよりなる医療部品 |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| WO1997042338A1 (en) | 1996-05-06 | 1997-11-13 | Chiron Corporation | Crossless retroviral vectors |
| US6048703A (en) | 1996-11-15 | 2000-04-11 | Cephalon, Inc. | Methods for detecting cell apoptosis |
| US6291643B1 (en) | 1997-06-05 | 2001-09-18 | Board Of Reports, The University Of Texas System | Apaf-1 an activator of caspase-3 |
| US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| SE0000597D0 (sv) * | 2000-02-24 | 2000-02-24 | Active Biotech Ab | Novel antibody |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002101071A2 (en) | 2001-06-07 | 2002-12-19 | Rigel Pharmaceuticals, Inc. | Cd43:modulators of mast cell degranulation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| JP2006502091A (ja) * | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| CU23228A1 (en) | 2002-04-29 | 2007-09-26 | Ct Ingenieria Genetica Biotech | FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME |
| US20080318297A1 (en) | 2004-06-23 | 2008-12-25 | Mitsuru Nakamura | Inhibition of Infiltration, and Cell Killing Agent |
| JP2008521828A (ja) * | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| WO2007048022A2 (en) | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
| CA2652703C (en) | 2006-06-07 | 2018-08-28 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| HUE026846T2 (en) | 2007-12-18 | 2016-08-29 | Bioalliance Cv | Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use |
-
2008
- 2008-12-18 HU HUE08863057A patent/HUE026846T2/en unknown
- 2008-12-18 DK DK08863057.9T patent/DK2245063T3/en active
- 2008-12-18 WO PCT/US2008/087515 patent/WO2009079649A1/en not_active Ceased
- 2008-12-18 US US12/338,934 patent/US7982017B2/en not_active Expired - Fee Related
- 2008-12-18 ES ES08863057.9T patent/ES2550757T3/es active Active
- 2008-12-18 RU RU2010129423/10A patent/RU2528738C2/ru not_active IP Right Cessation
- 2008-12-18 KR KR1020107011796A patent/KR101672271B1/ko not_active Expired - Fee Related
- 2008-12-18 AU AU2008338313A patent/AU2008338313B2/en not_active Ceased
- 2008-12-18 BR BRPI0820452-7A patent/BRPI0820452A2/pt not_active Application Discontinuation
- 2008-12-18 EP EP08863057.9A patent/EP2245063B1/en not_active Not-in-force
- 2008-12-18 CA CA2706502A patent/CA2706502C/en not_active Expired - Fee Related
- 2008-12-18 NZ NZ585959A patent/NZ585959A/xx not_active IP Right Cessation
- 2008-12-18 SG SG2012093167A patent/SG186669A1/en unknown
- 2008-12-18 CN CN2008801215817A patent/CN101918448A/zh active Pending
- 2008-12-18 CN CN201610109151.XA patent/CN105732813A/zh active Pending
- 2008-12-18 JP JP2010539824A patent/JP5568478B2/ja not_active Expired - Fee Related
- 2008-12-18 TW TW097149465A patent/TWI439545B/zh not_active IP Right Cessation
-
2010
- 2010-05-02 IL IL205487A patent/IL205487A/en active IP Right Grant
-
2011
- 2011-06-08 US US13/156,233 patent/US8568718B2/en not_active Expired - Fee Related
-
2013
- 2013-09-05 JP JP2013183896A patent/JP2013247963A/ja not_active Withdrawn
- 2013-09-24 US US14/035,731 patent/US9334329B2/en not_active Expired - Fee Related